Latest in News & Research

Margins >5 mm Often Needed to Achieve Tumor Clearance for Melanoma in Situ

Tumor location on cheek, larger preoperative size linked to requiring margins >5 mm to achieve tumor clearance

By Dermsquared Editorial Team | | February 28, 2024

Alopecia Patients Willing to Accept Substantial Risks for Hair Regrowth

Adults willing to accept mean three-year risk for serious infection, cancer, blood clots of 7.4, 2.5, and 9.3 percent, respectively

By Dermsquared Editorial Team | | February 28, 2024

Phototherapy for Vitiligo: An Overview of the Essentials

With an expanding array of therapeutic options emerging for vitiligo, phototherapy remains a safe and effective option

By Jenny She [1], Stephen Moore [1], Harrison P. Nguyen [1,2] | | February 28, 2024

Delayed Melanoma Care During Pandemic Proved Costly

Delayed diagnoses due to pandemic lockdowns tied to years of life lost

By Lori Solomon (HealthDay News) | | February 27, 2024

LAUNCH ALERT: Lifileucel (AMTAGVI) Approved for Treatment of Advanced Melanoma

FDA grants accelerated approval for the first T cell therapy for a solid tumor cancer

By Dermsquared Editorial Team | | February 22, 2024

Efficacy, Safety of Deucravacitinib Maintained Through Two Years

Exposure-adjusted incidence rates similar at one, two years for adverse events in patients with moderate-to-severe plaque psoriasis

By Dermsquared Editorial Team | | February 21, 2024

Risk for Subsequent Squamous Cell Carcinomas Rises With Number of Prior Ones

Median time interval after the previous cutaneous squamous cell carcinoma decreases after each subsequent cutaneous squamous cell carcinoma

By Dermsquared Editorial Team | | February 21, 2024

Clinical Markers Improve With IV Ertapenem for Hidradenitis Suppurativa

Significant reductions seen in mean Physician Global Assessment scores and in pain, C-reactive protein, IL-6, leukocytes

By Elana Gotkine (HealthDay News) | | February 21, 2024

Deep Learning Improves Diagnostic Accuracy for Skin Diseases

Both specialists and generalists were 4 percentage points less accurate for diagnosis of images of dark versus light skin

By Elana Gotkine (HealthDay News) | | February 16, 2024

Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

  • sNDA is supported by positive data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials and interim results from the Phase 3...
By Dermsquared Editorial Team | | February 16, 2024

FDA Approves Aurlumyn for Severe Frostbite

Newly approved medication lowers the need for amputation of fingers or toes

By Physician’s Briefing Staff (HealthDay News) | | February 15, 2024

Study Looks at Access to U.S. Burn Centers Using 2019 Data

Disparities seen in access to burn centers, with lower access in the South and West and for those with lower income

By Elana Gotkine (HealthDay News) | | February 14, 2024

Can Apremilast Improve Signs, Symptoms of Genital Psoriasis?

More patients receiving apremilast achieved modified static Physician Global Assessment of Genitalia response at week 16
By Dermsquared Editorial Team | | February 14, 2024

Many Survivors of Localized Melanoma Fear Recurrence

Thirty-eight of 51 survivors had FCRI-SF score above the threshold for clinical fear of cancer recurrence
By Dermsquared Editorial Team | | February 14, 2024

Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma

Greatest increased risk for melanoma-specific mortality seen for patients with SLNB-negative disease
By Elana Gotkine (HealthDay News) | | February 12, 2024

Health Care Costs, Resource Utilization Increased for Vitiligo Patients

Differences in all-cause, vitiligo-related health care costs remained higher for those on treatments with systemic effects/mental health diagnoses
By Elana Gotkine (HealthDay News) | | February 09, 2024

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide
By Elana Gotkine (HealthDay News) | | February 08, 2024

myDermRecruiter and Dermsquared™ Announce Exclusive Partnership to Revolutionize Dermatology Career Advancement

For Immediate Distribution & Release
By Dermsquared Editorial Team | | February 08, 2024

Metformin Use Not Significantly Linked to Pruritus

Canagliflozin significantly more likely to cause pruritus than insulin lispro or insulin glargine
By Dermsquared Editorial Team | | February 07, 2024

Does Reflectance Confocal Microscopy Increase Diagnostic Accuracy for BCC?

Adjunctive handheld RCM improves diagnostic accuracy of lesions clinically suspicious for basal cell carcinoma
By Dermsquared Editorial Team | | February 07, 2024

AAD Updates Guidelines for Management of Acne Vulgaris

Strong recommendations made for benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline
By Elana Gotkine (HealthDay News) | | February 05, 2024

Gender Minority Adults Are Vulnerable During Full Body Skin Exam

Gender queer and transgender individuals more likely to report discomfort than sexual minority cisgender females, males
By Elana Gotkine (HealthDay News) | | February 02, 2024

Dapsone, Sulfasalazine Beneficial as Adjuvants in Pemphigus Vulgaris

Evidence from review supports efficacy of dapsone and sulfasalazine as adjuvant therapies
By Dermsquared Editorial Team | | January 31, 2024

24 of 1200

Headline from the Week of February 09 - 15, 2026

Second Annual National Cancer Database Report Presented for 2022

By Elana Gotkine (HealthDay News) | | February 11, 2026

Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

By Elana Gotkine (HealthDay News) | | February 11, 2026